載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$2.04
+US$0.02 · +0.99%
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
前收盤價
US$2.04
+US$0.02 · +0.99%
盤中時間採用ET。市場資料可能有所延遲。
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
日內區間
目前US$2.04
52週區間
目前US$2.04
盤中時間採用ET。市場資料可能有所延遲。
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
日內區間
目前US$2.04
52週區間
目前US$2.04
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8.1萬 USD | 7.7萬 USD | 30.6萬 USD | 26.8萬 USD | 8.2萬 USD |
| 銷貨成本 | 16.4萬 USD | 8.2萬 USD | 21萬 USD | 19.3萬 USD | 3.7萬 USD |
| 毛利 | −8.3萬 USD | −5000 USD | 9.6萬 USD | 7.5萬 USD | 4.5萬 USD |
| 研究與開發 | 1317.1萬 USD | 1473萬 USD | 1522.5萬 USD | 1424.4萬 USD | 1101.9萬 USD |
| 銷售、一般及管理費用 | 2325萬 USD | 2190萬 USD | 2469.2萬 USD | 3148.3萬 USD | 2442.1萬 USD |
| 營業費用 | 3642.1萬 USD | 3663萬 USD | 3991.7萬 USD | 4572.7萬 USD | 3544萬 USD |
| 利息收入 | 458.5萬 USD | 274.7萬 USD | 164萬 USD | 45.6萬 USD | 14.5萬 USD |
| 利息支出 | 9000 USD | 2.8萬 USD | 5.5萬 USD | 6.1萬 USD | 74.6萬 USD |
| 折舊和攤銷 | 94萬 USD | 83.3萬 USD | 90萬 USD | 75.6萬 USD | 65.9萬 USD |
| 營業利益 | −3650.4萬 USD | −3663.5萬 USD | −3982.1萬 USD | −4565.2萬 USD | −3539.5萬 USD |
| 淨利 | −3192.8萬 USD | −3289.8萬 USD | −3624.2萬 USD | −4418.6萬 USD | −3500.9萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI188.05萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF80.6萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC20.94萬0.02%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM10萬0.09%1.17億 USD0.73%US$15.9402+0.25%
Avantis U.S. Small Cap Equity ETFAVSC1.09萬—30.82億 USD0.25%US$69.98+0.03%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.03萬0.00%455.91億 USD0.17%US$84.44+0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
